Healthcare provider profile · identity verified

Michael T Schulenberg, MD

Family Practice · EXCELSIOR, MN · NPI 1962402834

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	228	61
Gabapentin	Gabapentin	199	39
Amlodipine Besylate	Amlodipine Besylate	171	34
Levothyroxine Sodium	Levothyroxine Sodium	154	33
Omeprazole	Omeprazole	145	27
Oxycodone Hcl	Oxycodone Hcl	140	23
Lisinopril	Lisinopril	138	42
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	116	22
Pantoprazole Sodium	Pantoprazole Sodium	106	17
Metoprolol Succinate	Metoprolol Succinate	88	21
Mirtazapine	Mirtazapine	88	15
Quetiapine Fumarate	Quetiapine Fumarate	88	12
Losartan Potassium	Losartan Potassium	80	18
Simvastatin	Simvastatin	73	17
Trazodone Hcl	Trazodone Hcl	72	17
Bupropion Xl	Bupropion Hcl	71	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	69	12
Duloxetine Hcl	Duloxetine Hcl	68	12
Clonazepam	Clonazepam	66	suppressed
Allopurinol	Allopurinol	61	15
Lamotrigine	Lamotrigine	61	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	61	14
Furosemide	Furosemide	58	13
Potassium Chloride	Potassium Chloride	58	suppressed
Sertraline Hcl	Sertraline Hcl	54	13
Tamsulosin Hcl	Tamsulosin Hcl	51	13
Venlafaxine Hcl Er	Venlafaxine Hcl	49	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	48	13
Metoprolol Tartrate	Metoprolol Tartrate	47	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	44	18
Montelukast Sodium	Montelukast Sodium	44	suppressed
Tizanidine Hcl	Tizanidine Hcl	43	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	41	13
Lorazepam	Lorazepam	41	suppressed
Buspirone Hcl	Buspirone Hcl	40	suppressed
Fluticasone Propionate	Fluticasone Propionate	40	12
Metformin Hcl Er	Metformin Hcl	40	15
Alprazolam	Alprazolam	38	suppressed
Aripiprazole	Aripiprazole	38	suppressed
Prednisone	Prednisone	38	15
Famotidine	Famotidine	35	suppressed
Metformin Hcl	Metformin Hcl	35	11
Eliquis	Apixaban	34	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	34	suppressed
Celecoxib	Celecoxib	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Jardiance	Empagliflozin	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	12
Tramadol Hcl	Tramadol Hcl	30	suppressed
Valacyclovir	Valacyclovir Hcl	29	suppressed
Glipizide Er	Glipizide	28	suppressed
Morphine Sulfate Er	Morphine Sulfate	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Alendronate Sodium	Alendronate Sodium	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Varenicline Tartrate	Varenicline Tartrate	27	suppressed
Combipatch	Estradiol/Norethindrone Acet	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Atenolol	Atenolol	23	suppressed
Benztropine Mesylate	Benztropine Mesylate	23	suppressed
Carvedilol	Carvedilol	23	suppressed
Promethazine Hcl	Promethazine Hcl	23	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Baclofen	Baclofen	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Risperidone	Risperidone	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	13
Hydrocortisone	Hydrocortisone	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Estradiol	Estradiol	17	suppressed
Ozempic	Semaglutide	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Azithromycin	Azithromycin	16	12
Torsemide	Torsemide	16	suppressed
Vivitrol	Naltrexone Microspheres	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Finasteride	Finasteride	15	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Vilazodone Hcl	Vilazodone Hcl	15	suppressed
Amantadine	Amantadine Hcl	14	suppressed
Fluocinonide	Fluocinonide	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Lacosamide	Lacosamide	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Pentoxifylline	Pentoxifylline	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Alprazolam Er	Alprazolam	12	suppressed
Calcium Acetate	Calcium Acetate	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Nystatin	Nystatin	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Dexamethasone	Dexamethasone	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Metaxalone	Metaxalone	11	suppressed
Naproxen	Naproxen	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error